Immunotherapy versus chemotherapy as adjuvant therapy for resected MSI-H/dMMR colorectal cancer: real-world evidence informing precision strategies

Background​​Immunotherapy has demonstrated unique advantages in MSI-H/dMMR colorectal cancer (CRC) for its later-line, first-line in metastatic status, and neoadjuvant therapy. However, evidence regarding its value in postoperative adjuvant therapy remains limited.Methods​​We retrospectively analyze...

Whakaahuatanga katoa

Ngā taipitopito rārangi puna kōrero

Ngā kaituhi matua:	Haifeng Sun, Pin Lyu, Shuaixi Yang, Fuqi Wang, Sifan Zhai, Mengfei Zhao, Weitang Yuan, Quanbo Zhou
Hōputu:	Artigo
Reo:	Inglês
I whakaputaina:	Frontiers Media S.A. 2025-10-01
Rangatū:	Frontiers in Immunology
Ngā marau:	colorectal cancer microsatellite instability high mismatch repair deficient immunotherapy adjuvant therapy
Urunga tuihono:	https://www.frontiersin.org/articles/10.3389/fimmu.2025.1664684/full
Ngā Tūtohu:	Tāpirihia he Tūtohu Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!